Skip to main content
. 2021 Jul 19;38(8):4520–4540. doi: 10.1007/s12325-021-01823-6

Fig. 4.

Fig. 4

Overall survival for patients with mCRPC. A Overall survival after 1L start. B Overall survival after 2L start. C Overall survival after 3L start. Number of patients still observed at the specific point in time: 1040 patients participating in clinical trials or having a diagnosis of another cancer were excluded from the analysis; 466 patients participating in clinical trials or having a diagnosis of another cancer were excluded from the analysis; 300 patients participating in clinical trials or having a diagnosis of another cancer were excluded from the analysis